Hydroxyurea Associated Cutaneous Lesions: A Case Report
Open Access
- 19 August 2018
- journal article
- Published by Scientific Foundation SPIROSKI in Open Access Macedonian Journal of Medical Sciences
- Vol. 6 (8), 1458-1461
- https://doi.org/10.3889/oamjms.2018.320
Abstract
BACKGROUND: Hydroxyurea (HU) is an antimetabolite agent that interferes with the S-phase of cellular replication and inhibits DNA synthesis, with little or no effect on RNA or protein synthesis. It is used in the treatment of many myeloproliferative disorders (MD) and is particularly a first line treatment drug for intermediate to high-risk essential thrombocythemia. Although safe and very well tolerated by the patients suffering from MD, there have been numerous reports of a broad palette of cutaneous side effects associated with prolonged intake of the medication. These may include classical symptoms such as xerosis, diffuse hyperpigmentation, brown-nail discolouration, stomatitis and scaling of the face, hands, and feet or more serious side effects such as actinic keratosis lesions, leg ulcers and multiple skin carcinomas.CASE REPORT: We report a case of a 52-year-old man, on long-term therapy with HU for essential thrombocytosis, with several concurrent skin lesions. Despite the perennial use of HU, the cutaneous changes were neglected. The local dermatological examination revealed oval perimalleolar ulcer on the right leg, with dimensions 6 x 4 cm, clearly demarcated from the surroundings with regular margins, periulcerous erythema, with very deep and highly fibrinous bed of the ulcer, positive for bacterial infection. The ulcer was treated with topical wound therapy with alginate and parenteral antibiotics. The extended dermatological screening also showed two nummular lesions in the right brachial region, presenting as erythematous papules with sharp margins from the surrounding skin, gritty desquamation and dotted hyperpigmentations inside the lesion. Further dermoscopy and biopsy investigations confirmed a diagnosis of basal cell carcinoma. Nasal actinic keratosis was also noted. The patient was advised for discontinuing or substituting the HU therapy.CONCLUSION: We present this case to draw attention to the various cutaneous side effects that occur with perennial HU use and suggest an obligatory reference to a dermatological consult.Keywords
This publication has 14 references indexed in Scilit:
- Polycythemia vera treatment algorithm 2018Blood Cancer Journal, 2018
- Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk‐stratification and managementAmerican Journal of Hematology, 2015
- Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinomaHematology/Oncology and Stem Cell Therapy, 2014
- A case of hydroxyurea-induced leg ulcer after definitive treatment suspension in a patient affected by thrombocythemia: effectiveness of a new collagenase.2012
- A Hydroxyurea-induced Leg UlcerAnnals of Dermatology, 2009
- Hydroxyurea Induced Perimalleolar UlcersJournal of Korean Medical Science, 2006
- Toxicity and side effects of hydroxyurea used for primary thrombocythemiaPlatelets, 2005
- Mucocutaneous side effects of antineoplastic chemotherapy.Expert Opinion on Drug Safety, 2004
- Cutaneous Ulcers Associated with Hydroxyurea Therapy in Myeloproliferative DisordersLeukemia & Lymphoma, 1999
- Vasculitic leg ulcers in chronic myelogenous leukemiaThe American Journal of Medicine, 1985